Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stephen P. Ethier is active.

Publication


Featured researches published by Stephen P. Ethier.


Molecular Cancer Research | 2005

Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer

Véronique Gelsi-Boyer; Béatrice Orsetti; Nathalie Cervera; Pascal Finetti; Fabrice Sircoulomb; Carole Rougé; Laurence Lasorsa; Anne Letessier; Christophe Ginestier; Florence Monville; Séverine Esteyriès; José Adélaïde; Benjamin Esterni; Catherine Henry; Stephen P. Ethier; Frédéric Bibeau; Marie-Joelle Mozziconacci; Emmanuelle Charafe-Jauffret; Jocelyne Jacquemier; François Bertucci; Daniel Birnbaum; Charles Theillet; Max Chaffanet

In human carcinomas, especially breast cancer, chromosome arm 8p is frequently involved in complex chromosomal rearrangements that combine amplification at 8p11-12, break in the 8p12-21 region, and loss of 8p21-ter. Several studies have identified putative oncogenes in the 8p11-12 amplicon. However, discrepancies and the lack of knowledge on the structure of this amplification lead us to think that the actual identity of the oncogenes is not definitively established. We present here a comprehensive study combining genomic, expression, and chromosome break analyses of the 8p11-12 region in breast cell lines and primary breast tumors. We show the existence of four amplicons at 8p11-12 using array comparative genomic hybridization. Gene expression analysis of 123 samples using DNA microarrays identified 14 genes significantly overexpressed in relation to amplification. Using fluorescence in situ hybridization analysis on tissue microarrays, we show the existence of a cluster of breakpoints spanning a region just telomeric to and associated with the amplification. Finally, we show that 8p11-12 amplification has a pejorative effect on survival in breast cancer. (Mol Cancer Res 2005;3(12):655–67)


International Journal of Radiation Oncology Biology Physics | 2000

Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor

Geetha S Rao; Susan Murray; Stephen P. Ethier

PURPOSEnOverexpression of the ErbB family of growth factor receptors is present in a wide variety of human tumors and is correlated with poor prognosis. The purpose of this study was to determine the effects of a novel small molecule ErbB tyrosine kinase inhibitor, CI-1033, in combination with ionizing radiation on breast cancer cell growth and survival.nnnMATERIALS & METHODSnGrowth assays were performed on ErbB-overexpressing human breast cancer cells developed in our laboratory in the presence of 0.1-1.0 microM CI-1033 (Parke Davis). Clonogenic survival assays were performed in the presence of ionizing radiation with or without CI-1033. For some experiments, clonogen numbers, defined as the product of surviving fraction and total number of cells, were calculated at each time point during a course of multifraction radiation.nnnRESULTSnCI-1033 potently inhibited the growth of ErbB-overexpressing breast cancer cells. A single 48-h exposure of 1 microM CI-1033 resulted in growth inhibition for 7 days, whereas three times weekly administration resulted in sustained growth inhibition. Clonogenic survival was modestly decreased after a 7-day exposure to CI-1033. Exposure to both CI-1033 and radiation (6 Gy) yielded a 23-fold decrease in clonogenic survival compared to radiation alone. In a multifraction experiment, exposure to CI-1033 and three 5-Gy fractions of gamma radiation decreased the total number of clonogens in the population by 65-fold compared to radiation alone.nnnCONCLUSIONnCI-1033 results in potent growth inhibition and modest cytotoxicity of ErbB-overexpressing breast cancer cells, and has synergistic effects when combined with ionizing radiation. These data suggest that CI-1033 may have excellent clinical potential both alone and in combination with radiation therapy.


Clinical Cancer Research | 2004

Radiosensitization by Pan ErbB Inhibitor CI-1033 in Vitro and in Vivo

Mukesh K. Nyati; Divya Maheshwari; Sheela Hanasoge; Arun Sreekumar; Susan D. Rynkiewicz; Arul M. Chinnaiyan; Wilbur R. Leopold; Stephen P. Ethier; Theodore S. Lawrence

Purpose: Overexpression of the ErbB family of receptor tyrosine kinases has been associated with uncontrolled growth of many tumor types and, therefore, presents a promising molecular target for cancer therapy. CI-1033 is a small molecule tyrosine kinase inhibitor that differs from other 4-anilinoquinazolines by being a pan ErbB (instead of epidermal growth factor receptor-specific) irreversible (instead of reversible) inhibitor. Therefore, we investigated the antitumor effect of CI-1033 alone and in combination with ionizing radiation in vitro and in vivo. Experimental Design: We selected three human colon carcinoma cell-lines (LoVo, Caco-2, which express activated epidermal growth factor receptor and ErbB-2 family members, and SW620, which does not), and analyzed the effects of CI-1033 both in vitro and in vivo. For in vivo studies LoVo and Caco-2 cells were implanted s.c. in the flank of nude mice. After the tumor reached ∼100 mm3, treatment was initiated with 20 mg/kg of CI-1033 (orally once daily × 5 for 3 successive weeks), radiation treatment (a total of 30 Gy given in 2 Gy once daily × 5 for 3 successive weeks), or a combination of both CI-1033 and radiation treatment. Results: We found that exposure of LoVo and Caco-2, but not SW620 cells, to CI-1033 in the range of 1–3 μm could inhibit constitutive signaling by tyrosine kinases, arrest cell growth, inhibit cells in G1, stimulate expression of p53, and induce apoptosis. The inhibition of cell growth by CI-1033 seemed to produce only minimal radiosensitization in LoVo and Caco-2 cells. In contrast, the combination of CI-1033 and radiation produced significant (P < 0.0005 and P = 0.0002, respectively) and prolonged suppression of tumor growth in both the tumor types when compared with either treatment alone. Conclusions: These findings suggest that CI-1033 can increase the effectiveness of radiation therapy. The extent of suppression of tyrosine kinase activity by CI-1033, rather than the amount of activity in untreated cells, seemed to be more closely associated with the efficacy of combination treatment.


Journal of Clinical Investigation | 2000

The PHSRN sequence induces extracellular matrix invasion and accelerates wound healing in obese diabetic mice

Donna L. Livant; R. Kaye Brabec; Kotoku Kurachi; David Allen; Yanling Wu; Ronald C. Haaseth; Philip C. Andrews; Stephen P. Ethier; Sonja Markwart

The PHSRN sequence of the plasma fibronectin (pFn) cell-binding domain induces human keratinocytes and fibroblasts to invade the naturally serum-free extracellular matrices of sea urchin embryos. The potency of acetylated, amidated PHSRN (Ac-PHSRN-NH(2)) is significantly increased, making it more active on a molar basis than the 120-kDa cell-binding domain of pFn. Arginine is important to this activity because PHSAN and PHSEN are inactive, as is a randomized sequence peptide, Ac-HSPNR-NH(2). One treatment with Ac-PHSRN-NH(2) stimulates reepithelialization and contraction of dermal wounds in healing-impaired, obese diabetic C57BL6/KsJ db/db mice. Wound closure is equally rapid in treated db/db and db/+ mice and may be more rapid than in untreated nondiabetic db/+ littermates. In contrast, treatment with either Ac-HSPNR-NH(2) or normal saline (NS) has no effect. Analysis of sectioned db/db wounds shows that, in contrast to treatment with Ac-HSPNR-NH(2) or NS, a single Ac-PHSRN-NH(2) treatment stimulates keratinocyte and fibroblast migration into wounds, enhances fibroplasia and vascularization in the provisional matrix, and stimulates the formation of prominent fibers that may be associated with wound contraction.


Journal of Mammary Gland Biology and Neoplasia | 1996

Human breast cancer cell lines as models of growth regulation and disease progression.

Stephen P. Ethier

The routine isolation and culture of human breast cancer cells from patients samples has been a goal of breast cancer cell biologists for over 30 years. Despite extensive work in this area and the development of many human breast cancer cell lines, the proportion of patient samples that give rise to immortalized breast cancer cell lines is still disappointingly low. The majority of human breast cancer cell lines that have been established were isolated many years ago and have been grown continuously under poorly defined culture conditions. These cell lines have been useful for studies of the estrogen receptor biology in human breast cancer cells, in identifying growth factors synthesized by breast cancer cells, and for the characterization of genetic alterations in oncogenes and tumor suppressor genes present in these cells. More recently, tissue culture methods have improved, resulting in the ability to culture routinely normal human mammary epithelial cells of specific lineages and this has resulted in the development of new human breast cancer cell lines. The ability to isolate and culture normal and neoplastic human mammary epithelial cells under similar culture conditions has improved these models dramatically and has resulted in the identification of altered cellular phenotypes of human breast cancer cells.


Genes, Chromosomes and Cancer | 2000

Expression and mutational analyses of the human MAD2L1 gene in breast cancer cells

Melanie J. Percy; Kenute A. Myrie; Christopher K. Neeley; James Azim; Stephen P. Ethier; Elizabeth M. Petty

Breast cancer is a heterogeneous disorder in which most tumors display some degree of aneuploidy, especially those at later stages of the disease. Aneuploidy and associated chromosome instability may be important in the progression of mammary tumorigenesis. Aneuploidy is prevented during normal cell division in part through regulation of a mitotic spindle checkpoint where mitotic arrest prevents segregation of misaligned chromosomes into daughter cells at anaphase. Mitotic arrest genes, including the MAD family, which was originally characterized in yeast, help regulate normal function of the mitotic spindle checkpoint. Decreased expression of the human gene MAD2L1 was previously reported in a breast cancer cell line exhibiting chromosome instability and aneuploidy. To explore further the potential role of MAD2L1 in breast cancer, we analyzed MAD2L1 gene expression in 13 minimally to grossly aneuploid human breast cancer cell lines and found significant differences of expression in three lines. Sequence analysis of MAD2L1 cDNA in these as well as nine additional aneuploid breast cancer and five immortalized normal human mammary epithelial cell lines revealed one heterozygous frameshift (572 del A) mutation in a cancer cell line that demonstrated a high level of transcript expression. In addition, two 3′UTR sequence variants were noted in breast cancer cell lines. The 572 del A mutation creates a truncated MAD2 protein product. Further functional studies in primary breast tumors are therefore warranted to determine the potential role MAD2L1 may play in breast cancer.


Breast Cancer Research | 2000

Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE

Stacey L Tannheimer; Alnawaz Rehemtulla; Stephen P. Ethier

Statement of findingsThe fibroblast growth factor receptor (FGFR)2 gene has been shown to be amplified in 5-10% of breast cancer patients. A breast cancer cell line developed in our laboratory, SUM-52PE, was shown to have a 12-fold amplification of the FGFR2 gene, and FGFR2 message was found to be overexpressed 40-fold in SUM-52PE cells as compared with normal human mammary epithelial (HME) cells. Both human breast cancer (HBC) cell lines and HME cells expressed two FGFR2 isoforms, whereas SUM-52PE cells overexpressed those two isoforms, as well as several unique FGFR2 polypeptides. SUM-52PE cells expressed exclusively FGFR2-IIIb isoforms, which are high-affinity receptors for fibroblast growth factor (FGF)-1 and FGF-7. Differences were identified in the expression of the extracellular Ig-like domains, acid box and carboxyl termini, and several variants not previously reported were isolated from these cells.


Nutrition and Cancer | 1995

Carotenoids induce morphological changes in human mammary epithelial cell cultures

Cheryl L. Rock; Robin A. Kusluski; M. Matilda Galvez; Stephen P. Ethier

Epidemiological studies suggest that carotenoids may play a role in human breast carcinogenesis. To identify an anticarcinogenic mechanism, a laboratory model for examination of biologic effects is required. Efficacy of tetrahydrofuran (THF) for delivery of beta-carotene to a human mammary epithelial cell line has not been reported, and biologic effects of carotenoids on normal mammary epithelial cells or mammary epithelial cell lines have not been described. In these studies, we examined MCF-10A cells treated with 0.04%, 0.10%, and 0.35% THF (vol/vol) for morphological signs of toxicity and determined effects of THF on cell proliferation over a seven-day period. Cells treated with THF demonstrated a reduction in mean number of cells per dish (p < 0.05) but still underwent a 3.2- to 4.0-fold increase in cell number over the seven days. MCF-10A cells were also treated with a 7 mumol/l solution of beta-carotene and examined for morphological changes and effects on cell growth. Exposure to this concentration of carotenoid did not significantly affect proliferation but did induce the formation of cytoplasmic vacuoles similar to those seen in differentiating mammary epithelial cells. High-performance liquid chromatography analysis revealed a beta-carotene concentration of 0.004 nmol/10(6) cells in the treatment group. The effects of beta-carotene and the non-provitamin A carotenoid canthaxanthin were also examined in the in vitro cultures of primary human mammary epithelial cells obtained from reduction mammoplasties of two individuals. Exposure to these carotenoids induced morphological changes consistent with cellular differentiation and had a dramatic effect on the proliferative life span of these cells. Thus carotenoids may directly affect the proliferative capacity and differentiation of mammary epithelial cells, which may be among the chemoprotective activities of these compounds.


Cancer Research | 2004

Cleavage of β-Catenin by Calpain in Prostate and Mammary Tumor Cells

Jonathan Rios-Doria; Rainer Kuefer; Stephen P. Ethier; Mark L. Day

Mutations in the NH2-terminal regulatory domain of the β-catenin gene lead to aberrant stabilization and accumulation of the protein and increased TCF/LEF-dependent transcription. Although these mutations are common in some cancers, they are infrequent in prostate and breast cancer. We have found that metastatic prostate cancer specimens, obtained through a rapid autopsy tissue procurement program, expressed a novel Mr 75,000 proteolytic fragment of β-catenin (β-cat75). β-Cat75 was also expressed in multiple prostate and breast cancer cell lines and was closely associated with the activity of the calcium-dependent protease, calpain. In a prostate cancer cDNA microarray, m-calpain RNA levels were found to be significantly increased in metastatic disease compared with normal prostate. We showed calpain-dependent generation of β-cat75 in cell culture and in vitro. Molecular mapping revealed that calpain cleavage removed the NH2-terminal regulatory domain of the β-catenin protein. Treatment of MCF-7 cells with ionomycin led to increased accumulation of β-cat75 in the nucleus and TCF-dependent transcriptional activity. Overexpression of a similar β-catenin fragment that lacks the NH2-terminal 132 amino acids and has transforming potential activated TCF-dependent transcription. Given the low frequency of mutation-induced activation of β-catenin in prostate and breast cancers, proteolytic cleavage of β-catenin by calpain may represent a novel mechanism by which the protein is activated during tumorigenesis.


Breast Cancer Research and Treatment | 1999

Constitutive activation of pp125fak in newly isolated human breast cancer cell lines.

Kathleen M. Woods Ignatoski; Stephen P. Ethier

Our laboratory has developed twelve human breast cancer cell lines from primary and metastatic sites. In this report we demonstrate that eight of eight breast cancer cell lines examined exhibit constitutively tyrosine phosphorylated and enzymatically active endogenous pp125fak when grown in monolayer. The activation status of pp125fak in breast cancer cells in monolayer is significantly elevated over that exhibited by normal mammary epithelial cells cultured under the same conditions. Constitutive activation of pp125fak is the only characteristic so far studied that all of these breast cancer cell lines have in common. In contrast to HBC cells, tyrosine phosphorylation of pp125fak in HME cells was low or absent in monolayer culture but was induced to high levels by culturing the cells in Matrigel. Thus tyrosine phosphorylation and activation of pp125fak is a regulated process in normal mammary epithelial cells, but is constitutive in breast cancer cells. Finally, analysis of the ability of normal human mammary epithelial cells and breast cancer cell lines to grow under anchorage‐independent conditions indicated that normal human mammary epithelial cells rapidly and uniformly lost viability when not substrate‐attached, whereas all of the breast cancer cell lines survived for a 3‐week culture period. Furthermore, a subset of the breast cancer cell lines grew to form large colonies under anchorage‐independent conditions. Interestingly, pp125fak activation decreased dramatically in HBC cells cultured for two weeks in suspension, suggesting that activation of this kinase is not necessary for long‐term growth under anchorage‐independent conditions. These results suggest that constitutive activation of pp125fak results in preferential survival of human breast cancer cells under anchorage‐independent conditions but that activation of pp125fak is not the sole mediator of anchorage‐independent colony formation.

Collaboration


Dive into the Stephen P. Ethier's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tracy G. Ram

Washington State University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge